glp 1 pancreatic cancer risk The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the of Cancer: A U.S.-Based Cohort Study Evaluating the Rates of Pancreatitis
Description
This is the one area where the gap between the two is hard to miss
The first study, PIONEER 5, is reviewed above
[46] investigated the effectiveness of liraglutide (3.0 mg/day) and semaglutide (1.0 mg/week) after MBS in patients who regained 15.1% of their total body weight
& Liang, Y
A diagram of clinical practice recommendations for patients taking GLP-1 receptor agonists and dual GLP-1 and GIP receptor co-agonists before anaesthesia or sedation for surgical and endoscopic procedures is included with the updated recommendations and guidance (see Figure 1)
